Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

Completed

Phase 4 Results N/A

Summary of Purpose

This study will determine the safety and effectiveness of the drug Replagal for treating people with Fabry disease, an inherited metabolic disorder. In this disease, an enzyme called alpha-galactosidase A, which normally breaks down a lipid (fatty substance) known as ceramidetrihexoside, is missing or does not function properly. As a result, the lipid accumulates in the body, causing problems with the kidneys,...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 March 2008.

1 Nov 2004 30 Nov 2004 Unavailable 1 Dec 2005 1 Dec 2005 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Purpose: Treatment

Contacts

Not available